Trial · NCT00354770
N-Acetyl Cysteine in Trichotillomania
NCT00354770, Phase 2, Completed, University of Chicago; results first posted 2014-01-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. N-Acetyl Cysteine in Trichotillomania. Trials, record NCT00354770. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00354770
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- N-Acetyl Cysteine in Trichotillomania
- NCT number
- NCT00354770
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- University of Chicago
- Conditions
- Trichotillomania
- Interventions
- Placebo, N-Acetyl Cysteine
- First posted
- 2006-07-20
- Last updated
- 2023-02-23
- Results first posted
- 2014-01-15
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Massachusetts General Hospital Hairpulling Scale | Baseline and final visit after 12 weeks | There is no minimum or maximum score to quantify 'good' or 'poor' improvement based on this scale. The total score can range from 0-28 with zero being no problems to 28 being the most severe score one can receive.A total of 6 assessments were made, however only the final score (the score at the final visit after 12 weeks) was reported here to show the final outcome measure that was used in the final report of possible improvement and what was reported for final publication of data. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Massachusetts General Hospital Hairpulling Scale | Baseline and final visit after 12 weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Massachusetts General Hospital Hairpulling Scale | N-Acetyl Cysteine | MGH-HPS Baseline | 17.6 | Standard Deviation 4.64 | units on a scale |
| Massachusetts General Hospital Hairpulling Scale | Placebo | MGH-HPS Baseline | 16.7 | Standard Deviation 5.28 | units on a scale |
| Massachusetts General Hospital Hairpulling Scale | N-Acetyl Cysteine | MGH-HPS Final Visit After 12 Weeks | 10.4 | Standard Deviation 5.55 | units on a scale |
| Massachusetts General Hospital Hairpulling Scale | Placebo | MGH-HPS Final Visit After 12 Weeks | 16.0 | Standard Deviation 4.90 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | N-Acetyl Cysteine | 25 | |
| Overall Study | STARTED | Placebo | 25 | |
| Overall Study | COMPLETED | N-Acetyl Cysteine | 22 | |
| Overall Study | COMPLETED | Placebo | 22 | |
| Overall Study | NOT COMPLETED | N-Acetyl Cysteine | 3 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | N-Acetyl Cysteine | 0 | 25 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 2 | 25 | 2 |
| other | Nausea | Gastrointestinal disorders | N-Acetyl Cysteine | 0 | 25 | 0 |
| other | Nausea | Gastrointestinal disorders | Placebo | 1 | 25 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | N-Acetyl Cysteine | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | N-Acetyl Cysteine | 0 | 25 |
| Total, other adverse events | Placebo | 3 | 25 |
| Total, serious adverse events | N-Acetyl Cysteine | 0 | 25 |
| Total, serious adverse events | Placebo | 0 | 25 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| N-Acetyl Cysteine vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00354770
GET https://conductscience.org/api/trials/v1/NCT00354770/registered